4.3 Review

Progress in nonviral gene therapy for breast cancer and what comes next?

期刊

EXPERT OPINION ON BIOLOGICAL THERAPY
卷 17, 期 5, 页码 595-611

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2017.1305351

关键词

Breast cancer; gene therapy; nonviral nanovectors; immunotherapy; vaccine; clinical trials

资金

  1. Associazione Italiana Ricerca sul Cancro [AIRC] [6251]
  2. Fondazione Italiana Ricerca sul Cancro [FIRC] [18328]
  3. Fondazione Regionale per la Ricerca Biomedica (NANODRUG platform project)

向作者/读者索取更多资源

Introduction: The possibility of correcting defective genes and modulating gene expression through gene therapy has emerged as a promising treatment strategy for breast cancer. Furthermore, the relevance of tumor immune microenvironment in supporting the oncogenic process has paved the way for novel immunomodulatory applications of gene therapy.Areas covered: In this review, the authors describe the most relevant delivery systems, focusing on nonviral vectors, along with the description of the major approaches used to modify target cells, including gene transfer, RNA interference (RNAi), and epigenetic regulation. Furthermore, they highlight innovative therapeutic strategies and the application of gene therapy in clinical trials for breast cancer.Expert opinion: Gene therapy has the potential to impact breast cancer research. Further efforts are required to increase the clinical application of RNAi-based therapeutics, especially in combination with conventional treatments. Innovative strategies, including genome editing and stem cell-based systems, may contribute to translate gene therapy into clinical practice. Immune-based approaches have emerged as an attractive therapeutic opportunity for selected breast cancer patients. However, several challenges need to be addressed before considering gene therapy as an actual option for the treatment of breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据